We are live on ! Find out more
AXDX

Accelerate Diagnostics
AXDX

Delisted

AXDX was delisted on the 14th of May, 2025.

Back to rankings

109 hedge funds and large institutions have $513M invested in Accelerate Diagnostics in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 28

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

4% less funds holding

Funds holding: 113 → 109 (-4)

7% less capital invested

Capital invested by funds: $551M → $513M (-$38.9M)

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

53% less call options, than puts

Call options by funds: $5.37M | Put options by funds: $11.4M

Holders
109
Holders Change
-4
Holders Change %
-3.54%
% of All Funds
2.15%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
14
Increased
30
Reduced
28
Closed
18
Calls
$5.37M
Puts
$11.4M
Net Calls
-$6M
Net Calls Change
-$5.3M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$12.4M
2
CC
Chicago Capital
Illinois
+$7.14M
3
Axa
Axa
France
+$4.13M
4
GAM
Griffin Asset Management
New York
+$2.97M
5
AG
Artal Group
Luxembourg
+$1.65M

Top Sellers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
-$4.27M
2
CS
Credit Suisse
Switzerland
-$4.27M
3
NCGI
Next Century Growth Investors
Minnesota
-$3.35M
4
First Trust Advisors
First Trust Advisors
Illinois
-$2.43M
5
OIM
Oracle Investment Management
Connecticut
-$2.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
BAMCO Inc
26
BAMCO Inc
New York
$4.39M – – –
EVM
27
Eaton Vance Management
Massachusetts
$3.77M – – –
UBS Group
28
UBS Group
Switzerland
$3.5M +$750K +4,542 +28%
Charles Schwab
29
Charles Schwab
California
$2.79M +$53.5K +324 +2%
OCMI
30
Oaktop Capital Management II
New Jersey
$2.62M – – –
Citadel Advisors
31
Citadel Advisors
Florida
$2.38M +$1.28M +7,766 +122%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$2.01M +$86.2K +522 +5%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$1.57M +$257K +1,558 +20%
CI
34
Chartist Inc
California
$1.09M – – –
PPA
35
Parametric Portfolio Associates
Washington
$989K +$10.4K +63 +1%
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$988K +$428K +2,593 +80%
Swiss National Bank
37
Swiss National Bank
Switzerland
$970K +$31.4K +190 +3%
RCM
38
Raging Capital Management
New Jersey
$953K – – –
TWA
39
TCI Wealth Advisors
Arizona
$939K – – –
Two Sigma Investments
40
Two Sigma Investments
New York
$891K +$870K +5,274 New
Goldman Sachs
41
Goldman Sachs
New York
$876K +$70.6K +428 +9%
CIBC Private Wealth Group
42
CIBC Private Wealth Group
Georgia
$770K -$18.2K -110 -2%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$704K -$24.8K -150 -3%
TIM
44
Thompson Investment Management
Wisconsin
$654K +$82.5K +500 +15%
AllianceBernstein
45
AllianceBernstein
Tennessee
$646K -$33K -200 -5%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$624K +$4.29K +26 +0.7%
Barclays
47
Barclays
United Kingdom
$522K -$602K -3,650 -54%
CM
48
Caption Management
Oklahoma
$487K -$680K -4,120 -59%
UBS AM
49
UBS AM
Illinois
$459K -$990 -6 -0.2%
SWM
50
SeaCrest Wealth Management
New York
$454K -$70K -424 -14%
1
2
3 4 5

AXDX Hedge Fund Activity: Q4 2019 in Review

109 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2019, worth a combined $513M — down 7.1% from $551M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of AXDX and 14 opened new positions — a net loss of 4 holders — while 28 trimmed existing stakes and 30 added.

The largest buyer was Fidelity Investments, adding an estimated $12.4M. The largest seller was William Blair & Company, cutting an estimated $4.27M.

  • 109 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2019, down from 113 in Q3 2019.
  • Funds reported $513M of Accelerate Diagnostics stock for Q4 2019, down 7.1% quarter-over-quarter.
  • 14 funds opened new Accelerate Diagnostics positions in Q4 2019 and 18 closed out, a net change of -4 holders.
  • The largest Accelerate Diagnostics buyer in Q4 2019 was Fidelity Investments, an estimated $12.4M added.
  • The largest Accelerate Diagnostics seller in Q4 2019 was William Blair & Company, an estimated $4.27M sold.

Based on aggregated 13F filings for Q4 2019.